Results 11 to 20 of about 4,503 (108)

4β-Hydroxycholesterol Signals From the Liver to Regulate Peripheral Cholesterol Transporters [PDF]

Frontiers in Pharmacology, 2020
Activation of pregnane X receptor (PXR) elevates circulating 4β-hydroxycholesterol (4βHC), an agonist of liver X receptor (LXR). PXR may also regulate 25-hydroxycholesterol and 27-hydroxycholesterol.
Tuire Salonurmi, Tuire Salonurmi, Heba Nabil, Heba Nabil, Heba Nabil, Justiina Ronkainen, Justiina Ronkainen, Tuulia Hyötyläinen, Heidi Hautajärvi, Markku J. Savolainen, Markku J. Savolainen, Markku J. Savolainen, Ari Tolonen, Matej Orešič, Päivi Känsäkoski, Jaana Rysä, Jukka Hakkola, Jukka Hakkola, Jukka Hakkola, Janne Hukkanen, Janne Hukkanen, Janne Hukkanen   +21 more
doaj   +4 more sources

Role of oxysterol 4β-hydroxycholesterol and liver X receptor alleles in pre-eclampsia [PDF]

Annals of Medicine
Background Liver X receptors (LXRs) are expressed in placenta and may be associated with pre-eclampsia (PE). Oxysterols act as agonists for LXRs. We recently proposed a new blood pressure-regulating circuit with oxysterol 4β-hydroxycholesterol (4βHC ...
Lassi Kaartinen, Tiina Jääskeläinen, Eeva Sliz, Gamze Yazgeldi Gunaydin, Satu Wedenoja, Shintaro Katayama, Eero Kajantie, Valtteri Rinne, Seppo Heinonen, Juha Kere, Heta Merikallio, Eeva Sliz, Hannele Laivuori, Janne Hukkanen   +13 more
doaj   +5 more sources

No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. [PDF]

PLoS ONE, 2015
PURPOSE:To investigate the effect of vitamin D3 on hepatic Cytochrome P450 enzyme (CYP) 3A4 in patients with abnormal glucose regulation using the endogenous marker 4β-hydroxycholesterol (4β-OHC):cholesterol ratio.
Buster Mannheimer, Henrik Wagner, Claes-Göran Östenson, Ulf Diczfalusy   +3 more
doaj   +3 more sources

PXR and 4β-Hydroxycholesterol Axis and the Components of Metabolic Syndrome [PDF]

Cells, 2020
Pregnane X receptor (PXR) activation has been found to regulate glucose and lipid metabolism and affect obesity in response to high-fat diets. PXR also modulates vascular tone.
Janne Hukkanen, Jukka Hakkola
doaj   +3 more sources

Liver X Receptor Agonist 4β‐Hydroxycholesterol as a Prognostic Factor in Coronary Artery Disease [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Regardless of progress in treatment of coronary artery disease (CAD), there is still a significant residual risk of death in patients with CAD, highlighting the need for additional risk stratification markers.
Roosa Rahunen, Mikko Tulppo, Valtteri Rinne, Samuli Lepojärvi, Juha S. Perkiömäki, Heikki V. Huikuri, Olavi Ukkola, Juhani Junttila, Janne Hukkanen   +8 more
doaj   +4 more sources

Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation [PDF]

Journal of Lipid Research, 2013
Several previous studies have shown that renal failure decreases not only renal elimination but also metabolic clearance of drugs, particularly those metabolized by CYP3A.
Yosuke Suzuki, Hiroki Itoh, Fuminori Sato, Kanako Kawasaki, Yukie Sato, Takashi Fujioka, Yuhki Sato, Keiko Ohno, Hiromitsu Mimata, Satoshi Kishino   +9 more
doaj   +2 more sources

Application of Virtual Twin PBPK Models in Individuals with Obesity via CYP3A4 Phenotyping Using Endogenous Biomarker Data. [PDF]

Clin Pharmacol Ther
Plasma 4β‐hydroxycholesterol (4β‐OHC) normalized for the levels of its parent cholesterol (4β‐OHC/C) is an endogenous biomarker for hepatic CYP3A4. This study evaluated CYP3A4 activity longitudinally in individuals while their obesity status was changing. 4β‐OHC/C was measured pre‐surgery (n = 54) and 2 years after Roux‐en‐Y gastric bypass (n = 30) and
Izat N, Kangne H, Jansson-Löfmark R, Hertel JK, Rostami-Hodjegan A, Robertsen I, Galetin A.   +6 more
europepmc   +2 more sources

Correction: Taya et al. Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity. Molecules 2023, 28, 1576 [PDF]

Molecules
In the original publication [...]
Yuki Taya, Mari Mizunaga, Shunsuke Nakao, Mirinthorn Jutanom, Naoki Shimizu, Yukihiro Nomura, Kiyotaka Nakagawa   +6 more
doaj   +2 more sources

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients. [PDF]

Br J Clin Pharmacol
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Rasmussen ASB, Koch MR, Rank CU, Andersen CL, Weimann A, Thastrup M, Yang T, Lund TM, Christensen IJ, Nielsen F, Stage TB, Jensen SB, Andersen MK, Schmiegelow K, Dalhoff K.   +14 more
europepmc   +2 more sources

Serum 4β-hydroxycholesterol increases during fluconazole treatment. [PDF]

Eur J Clin Pharmacol, 2021
Purpose: The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity.
Lütjohann D, Stellaard F, Kerksiek A, Lötsch J, Oertel BG.   +4 more
europepmc   +2 more sources